Clinical Trial Update: Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating ONO-7475 in combination with osimertinib for EGFR mutation-positive non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ONO-7475
• Osimertinib (osimertinib)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED